TECH logo

BIO-TECHNE CORP

TECHNASDAQ
πŸ† #817 by market capEarnings Nov 4US Equity
$72.38β–Ό $0.13 (βˆ’0.18%)
πŸŒ™ After hours$72.38β–² 0.00%Regular close Β· extended-hours price shown
πŸ””
Track TECH
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 0.2%
7dβ–Ό 0.2%
14dβ–² 0.1%
30dβ–² 0.0%
ytdβ–² 23.1%
1yβ–² 38.6%
🏦Market Cap
$11.33B
Mid Cap
πŸ“ˆRevenue Growth (YoY)
-0.4%
Declining
πŸ“ŠGross Margin
65.8%
High
πŸ’΅FCF Margin
21.7%
Strong
βš–οΈP/S Ratio
9.3x
Elevated
Otter Score
68
Fair

Trading Snapshot

Day Range
$71.88 – $72.96
52-Week Range
$43.20 – $72.69
Volume
$3.78B
Avg Volume
$4.81B
Shares Outstanding
156.6M
Next Earnings
Nov 17, 2026

Fundamentals Snapshot

Annual Revenue
$1.22B
Last Q Revenue
$321M
P/E Ratio
62.0
P/S Ratio
9.3x
EPS (TTM)
$1.17
Dividend Yield
0.44%
Dilution (1yr)
+0.0%

Why Investors Own TECH

  • βœ“High-growth profile β€” revenue up -3.1% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 60% gross margin and 12% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

TECH logo

BIO-TECHNE CORP

TECH
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$1.2Bβ–Ό βˆ’0.4% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
65.8%β–² +1.5% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$252Mβ–² +146.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$263Mβ–² +2.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
157.0Mβ–² +0.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$24Mβ–² +$154M YoY
StockOtter Β· stockotter.space

About BIO-TECHNE CORP

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
68/100

Analyst Price Target

β“˜
Average Target
$70.25
β–Ό βˆ’2.9% Downside
High Target$87.70
Low Target$55.62
Based on 13 analysts

Latest News & Updates

PRNewsWireΒ·8h ago

INTURAI PROVIDES DEFENCE TECH COMPETITION RESULTS AND COMPANY UPDATE

(CSE: URAI / OTC: URAIF / FSE: 3QG0) investor@inturai.com DomeCommand, the drone command-and-control platform the Company recently acquired, won first and third place in the two-day team integration category at the Singa

Defense WorldΒ·1d ago

Bio-Techne (NASDAQ:TECH) Reaches New 52-Week High – Time to Buy?

Shares of Bio-Techne Corp (NASDAQ: TECH - Get Free Report) hit a new 52-week high on Monday. The company traded as high as $72.70 and last traded at $72.70, with a volume of 2660 shares trading hands. The stock had previ

Newsfile CorpΒ·1d ago

Zhibao Technology Signs Definitive Agreement to Acquire NEXSYS TECH for Planned AI Computing Infrastructure Business

KEY HIGHLIGHTS Strategic Acquisition: Zhibao Technology Inc. (NASDAQ: ZBAO) ("Zhibao," "we," or the "Company") has entered into a definitive Merger and Acquisition Agreement dated September 28, 2026, to acquire 100% of t

PRNewsWireΒ·6d ago

Bio-Techne Shareholders Approve Acquisition by Merck KGaA, Darmstadt, Germany

MINNEAPOLIS, Sept. 23, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) ("Bio-Techne"), a global provider of life science tools, reagents and diagnostic products, announced that Bio-Techne shareholders voted to

PRNewsWireΒ·7d ago

Bio-Techne Opens New Customer Experience Center in DΓΌsseldorf to Accelerate Scientific Discovery and Customer Collaboration

New flagship facility provides hands-on access to Bio-Techne technologies, workflows and scientific expertise Regional hub will support researchers and organizations across theΒ DACH and broader EMEA regions Center streng

Zacks Investment ResearchΒ·18d ago

Why Is Techne (TECH) Down 0.1% Since Last Earnings Report?

Techne (TECH) reported earnings 30 days ago. What's next for the stock?